Singapore markets close in 6 hours 32 minutes
Straits Times Index
3,301.98 -12.07 (-0.36%) Nikkei
39,106.47 +36.79 (+0.09%) Hang Seng
19,255.70 -380.52 (-1.94%) FTSE 100
8,424.20 +3.94 (+0.05%) Bitcoin USD
71,005.84 +4,389.70 (+6.59%) CMC Crypto 200
1,510.31 +155.89 (+11.52%)
PT Kalbe Farma Tbk. (KLBF.JK)
Jakarta - Jakarta Delayed price. Currency in IDR
Add to watchlist
As of 09:18AM WIB. Market open.
| Previous close | 1,530.00 |
| Open | 1,535.00 |
| Bid | 1,505.00 x 0 |
| Ask | 1,510.00 x 0 |
| Day's range | 1,500.00 - 1,535.00 |
| 52-week range | 1,375.00 - 2,160.00 |
| Volume | |
| Avg. volume | 33,970,360 |
| Market cap | 69.615T |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 24.23 |
| EPS (TTM) | 62.12 |
| Earnings date | 02 Aug 2024 - 03 Aug 2024 |
| Forward dividend & yield | 38.00 (2.68%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | 1,663.60 |
Business WireGenexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
SEOUL, South Korea, October 23, 2023--Genexine (KQ 095700, CEO Sungjune Hong), a publicly-listed clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, together with PT Kalbe Genexine Biologics (KGbio), a joint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma that focused on bringing biologics medical innovation to international markets, announced the approval of its
© 2024 Yahoo. All rights reserved.